Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
作者信息
Seftel Matthew D
机构信息
Hematologist, University of British Columbia, Vancouver, BC.
出版信息
CMAJ. 2020 May 4;192(18):E483. doi: 10.1503/cmaj.75427.
Abstract
摘要
相似文献
1
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.阿奇霉素在治疗新型冠状病毒肺炎中的其他安全性考量。
CMAJ. 2020 May 4;192(18):E483. doi: 10.1503/cmaj.75427.
2
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.阿奇霉素联合羟氯喹治疗因 2019 冠状病毒病（COVID-19）入住重症监护病房的患者：随机对照试验 AZIQUINE-ICU 的方案。
Trials. 2020 Jul 8;21(1):631. doi: 10.1186/s13063-020-04566-x.
3
Does hydroxychloroquine prevent the transmission of COVID-19?羟氯喹能预防新型冠状病毒肺炎的传播吗？
Ann Rheum Dis. 2020 Jun;79(6):e60. doi: 10.1136/annrheumdis-2020-217501. Epub 2020 Apr 15.
4
Taking the Longer View of COVID-19.从更长远的视角看待新冠疫情。
Oncologist. 2020 Jun;25(6):455-457. doi: 10.1634/theoncologist.2020-0313. Epub 2020 Apr 27.
5
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].[羟氯喹啉。冠状病毒大流行时期心脏病学的观点]
Medicina (B Aires). 2020;80(3):271-274.
6
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.氯喹和羟氯喹作为对抗新型冠状病毒肺炎的现有武器。
Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4.
7
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.在重症新型冠状病毒肺炎患者中使用氯喹时的获益与风险
S Afr Med J. 2020 Apr 2;110(5):12903. doi: 10.7196/SAMJ.2020.v110i5.14761.
8
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
9
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.美国羟氯喹、氯喹和阿奇霉素门诊处方趋势，2019 年 10 月至 2020 年 3 月。
JAMA Intern Med. 2020 Oct 1;180(10):1384-1386. doi: 10.1001/jamainternmed.2020.2594.
10
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
引用本文的文献
1
Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.氯喹和羟氯喹与人细胞色素 P450 酶和药物转运体的代谢和相互作用。
Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
2
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).血红素加氧酶 1（HMOX1）通路作为 2019 年新型冠状病毒（COVID-19，即 SARS-CoV-2）治疗和预防的有前途靶点。
Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.
本文引用的文献
1
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
2
Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.阿奇霉素对异基因造血干细胞移植后无气流下降生存期的影响：ALLOZITHRO随机临床试验
JAMA. 2017 Aug 8;318(6):557-566. doi: 10.1001/jama.2017.9938.
Zotero 插件